Novel Immunoassay Developed to Diagnose Dengue
|
By LabMedica International staff writers Posted on 17 Jan 2016 |

Image: Novel Immunoassay for Dengue virus (Photo courtesy of Fraunhofer IZI).

Image: The immature dengue viral particle. Notable are the 60 protein “spikes” which jut from the surface, making the immature particle far less smooth than the mature form (Photo courtesy of Purdue University).
Until now, it has been difficult to diagnose whether someone is suffering from dengue fever or whether they have contracted another flavivirus, such as yellow fever, West Nile virus, or Tick-borne encephalitis virus (TBEV).
Although there are already tests on the market, but none of them can tell the difference between these individual flaviviruses and if a definitive diagnosis is required, a sample of the patient's blood has to be sent to a high-security laboratory for analysis.
Scientists at the Fraunhofer Institute for Cell Therapy and Immunology (Leipzig, Germany) have developed a definitive antibody test for Dengue virus. Conventional antibody tests are performed by the health professional who draws the patient's blood. If infected with the Dengue virus, the blood will contain specific antibodies produced by the body to attack the intruder. The laboratory staffer then applies the blood to a test platform with dengue antigens that systematically bind with these antibodies. If, after a set reaction time, antibodies are found on the platform, the physician will assume that the patient has been infected with the Dengue virus. The catch is that, although the antigens bind with the antibodies according to the lock and key principle, they almost always do so at the same site as all other flaviviruses. This means that, even when the test is positive, no one can say for sure that it is actually a case of dengue.
The scientists hope that their test will hit the market around one year from now. In a further step, they are working on ways to differentiate between the four strains of the dengue pathogen. This could be an important breakthrough: Anyone who has survived a dengue-related illness has then acquired immunity against that specific pathogen, but when it comes to the other three strains, that person is at even greater risk. This is because the antibodies they produced to combat the first bout of dengue fever actually help the new virus to spread and make it much harder for that person to recover.
Dr. Sebastian Ulbert, Head of the Working Group on Vaccine Technologies, said, “We've succeeded in developing the first ever antibody test for dengue infections that is capable of distinguishing between dengue and other flaviviruses. Since our test is also based on detecting antibodies, it's just as cheap and easy to run as its conventional counterparts. Our test system has the potential to differentiate between the four viral strains.” The new method can easily be integrated into existing test setups and at no extra cost to manufacturers.
Related Links:
Fraunhofer Institute for Cell Therapy and Immunology
Although there are already tests on the market, but none of them can tell the difference between these individual flaviviruses and if a definitive diagnosis is required, a sample of the patient's blood has to be sent to a high-security laboratory for analysis.
Scientists at the Fraunhofer Institute for Cell Therapy and Immunology (Leipzig, Germany) have developed a definitive antibody test for Dengue virus. Conventional antibody tests are performed by the health professional who draws the patient's blood. If infected with the Dengue virus, the blood will contain specific antibodies produced by the body to attack the intruder. The laboratory staffer then applies the blood to a test platform with dengue antigens that systematically bind with these antibodies. If, after a set reaction time, antibodies are found on the platform, the physician will assume that the patient has been infected with the Dengue virus. The catch is that, although the antigens bind with the antibodies according to the lock and key principle, they almost always do so at the same site as all other flaviviruses. This means that, even when the test is positive, no one can say for sure that it is actually a case of dengue.
The scientists hope that their test will hit the market around one year from now. In a further step, they are working on ways to differentiate between the four strains of the dengue pathogen. This could be an important breakthrough: Anyone who has survived a dengue-related illness has then acquired immunity against that specific pathogen, but when it comes to the other three strains, that person is at even greater risk. This is because the antibodies they produced to combat the first bout of dengue fever actually help the new virus to spread and make it much harder for that person to recover.
Dr. Sebastian Ulbert, Head of the Working Group on Vaccine Technologies, said, “We've succeeded in developing the first ever antibody test for dengue infections that is capable of distinguishing between dengue and other flaviviruses. Since our test is also based on detecting antibodies, it's just as cheap and easy to run as its conventional counterparts. Our test system has the potential to differentiate between the four viral strains.” The new method can easily be integrated into existing test setups and at no extra cost to manufacturers.
Related Links:
Fraunhofer Institute for Cell Therapy and Immunology
Latest Microbiology News
- WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
- Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
- New WHO Tools Address Gaps in Antimicrobial Resistance Testing
- Complete Malaria Genomes Could Improve Species Identification and Surveillance
- Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
- Automated Microbial Identification and Susceptibility System Gains FDA Clearance
- Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
- Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
- Common Genetic Variant Increases Risk of Bacterial Pneumonia
- Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections
- Stool Testing Predicts UTI Risk and Guides Antibiotic Selection
- Repeat Prenatal STI Screening and Treatment May Reduce Preterm Births
- Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea
- Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
- Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
- Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







